Abstract:OBJECTIVE:To study the differences of objective response rate (ORR), side effects and survival among patients with limited-stage small cell lung cancer (LD-SCLC), who received concurrent chemoradiotherapy, sequential chemoradiotherapy or chemotherapy alone, and to analyze the influencing factors on their survival. METHODS:One hundred and sixty-six patients diagnosed as LD-SCLC in Peking Union Medical College Hospital from January 2000 to December 2009 were included in this study. The differences of objective response rates, side effects and survival rates were analyzed by χ2 test. Kaplan-Meier test was used to calculate the overall survival (OS) and progress-free survival (PFS). Cox regression was used to detect the influencing factors on survival time of the patients. RESULTS:The patients were divided into three groups: concurrent chemoradiotherapy (49 cases), sequential chemoradiotherapy (62 cases) and chemotherapy alone (55 cases). The chemotherapy was based on CE/EP regimen, with an average cycle of 5.2. Radiotherapy was of a common or 3-dimensional conformal technology, for regular segmentation irradiation with an average dose of 49.6 Gy. The total ORR was 73.4%, OS and PFS were 22.9 months and 10.8 months, 1, 3, 5-year survival rates were 82.7%, 31.8%, 18.6%, respectively. For the concurrent group, sequential group and chemotherapy alone group, the ORR was 89.4%, 67.2% and 66.0%, respectively. Compared the chemotherapy alone group and concurrent group with the sequential group, there were significant differences (P<0.05). For the concurrent group, sequential group and chemotherapy alone group, the median OS was 29.7 months, 22.6 months, and 19.5 months; the median PFS was 12.7 months, 10.8 months, and 9.8 months, respectively, with a non-significant difference between each two groups (P>0.05). For the concurrent group, sequential group and chemotherapy alone group, the 1-year survival rates were 91.1%, 86.3%, and 65.6%, the 3-year survival rates were 44.2%, 28.3% and 22.8%, and the 5-year survival rates were 24.2%, 21.4% and 11.1%, respectively, with significant differences among them (P<0.05). The major side effects were myelosuppression, gastrointestinal reactions, radiation pneumonia and radiation esophagitis. For the concurrent group, sequential group and chemotherapy alone group, the incidence of myelosuppression were 84.4%, 76.8% and 60.0%, respectively, with a significant difference (P=0.008) between the concurrent group and chemotherapy alone group. For the concurrent group and sequential group, the incidences of radiation pneumonia were 22.2% and 22.9%, with a non-significant difference (P=0.940). The incidences of radiation esophagitis were 47.2% and 16.7%, respectively, with a significant difference (P=0.002). Multivariate analysis showed that OS was significantly associated with gender (P=0.018) and ECOG score (P=0.009), and PFS was significantly associated with gender (P=0.050). CONCLUSIONS:For LD-SCLC, concurrent chemoradiotherapy can significantly increase the objective response rate. Concurrent chemoradiotherapy and sequential chemoradiotherapy compared with chemotherapy alone can extend survival, and concurrent chemoradiotherapy is better, but the differences among the three regimens are not significant. Gender and ECOG score are important influencing factors of survival.

Long-term curative effect of multimodality therapy for non-small cell lung cancer

Curative Effects, Prognostic Factors, and Adverse Reactions of Different Treatment Modalities of Chemotherapy in Patients with Non-Small Cell Lung Cancer

Analyses of Prognostic Factors in Cases of Non-Small Cell Lung Cancer with Multiple Brain Metastases

Radiochemotherapy Combined with Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Locally Advanced Non-Small Cell Lung Cancer:A Preliminary Study

Observation on Curative Effects of Concurrent Radiotherapy and Chemotherapy for Advanced Non-small-cell Lung Cancer

Effects of Concurrent Chemoradiotherapy and Sequential Radiotherapy and Chemotherapy on Progression-free Survival in Patients with Non-small Cell Lung Cancer

Effect Analysis of Concurrent Chemo-radiotherapy for the Limited-stage Small-cell Lung Cancer

Analysis of Prognostic Factors of Sequential Treatment in 355 Patients with Advanced Non-Small Cell Lung Cancer

Clinical research of palliative radiotherapy for patients with stage Ⅳ non small cell lung cancer

[Therapeutic Effects and Prognostic Factors for the Limited-Stage Small Cell Lung Cancer Treated with Multidisciplinary Therapy].

P3-245: Survival Improvement During Two Decades in Stage IIIA NSCLC Patients from Single Institution

Effects of different radiotherapy timing on outcomes of limited-stage non-small-cell lung cancer with induction chemotherapy

Therapeutic effects of concurrent stereotactic radiochemotherapy or surgery plus chemotherapy in stage Ⅲ A non-small cell lung cancer

[Advances in Multimodality Therapy of Lung Cancer].

Observation of Short-Term Effect for Intensity Modulated Radiotherapy and Chemotherapy in Non-Small Cell Lung Cancer

Clinical Study on Accurate Radiotherapy Combined with Chemotherapy in the Treatment of Middle and Advanced Non-Small Cell Lung Cancer

Comparative Study of the Theraputic Effects on Medium-Term and Late NSCLC

Multidisciplinary Combined Modality Therapy for Stage Ⅲ Non-Small Cell Lung Cancer

A Prospective Study on Concurrent Chemotherapy and Thoracic Three - Dimensional Radiotherapy for Stage IV Non - Small Cell Lung Cancer ( 2 ) — the Impact of Different Metastasis Organs on Survival

Comparison of the clinical effect between the synchronization chemoradiotherapy and sequential chemoradiotherapy in the treatment of stage Ⅲ non-small cell lung cancer

A prospective study on concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage IV non-small cell lung cancer （4）--The impact of response on survival